T

Tarsus Pharmaceuticals

Develops FDA-approved ophthalmic therapies

Director Pharmacokinetics & Bioanalysis

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • An advanced degree in pharmacokinetics, pharmaceutical sciences, pharmacology, chemistry, biochemistry, biomedical engineering, or a related scientific field and a minimum of 10 years of relevant experience; candidates with a bachelor’s or master’s degree and equivalent relevant experience of more than 15 years are also encouraged to apply.
  • Substantial industry experience in pharmacokinetics, DMPK, bioanalysis, clinical pharmacology, pharmacometrics, or a related drug-development discipline.
  • A track record of driving impact across drug discovery, nonclinical development, and/or clinical development programs.
  • Deep, broad command of pharmacokinetics, drug metabolism, bioanalysis, and how PK/PD data can sharpen development decisions.
  • Experience working with external research organizations, laboratories, or other development partners.
  • Experience preparing, reviewing, or contributing to scientific and regulatory documentation.
  • Strong written, verbal, organizational, and project-management skills.
  • A collaborative, proactive scientist who can work in a fast-paced, matrixed environment.
  • An entrepreneurial mindset and an owner’s sense of accountability.

Responsibilities

  • Shape the scientific and strategic direction of pharmacokinetics, drug metabolism, bioanalysis, and translational PK/PD across the portfolio.
  • Design pharmacokinetic strategies tailored to each stage of development; lead internal and external activities; and partner with cross-functional teams on candidate selection, clinical dose planning, and regulatory submissions.
  • Serve as the pharmacokinetics and DMPK expert, shaping strategy across programs.
  • Architect and drive PK, DMPK, bioanalytical, and translational PK/PD strategies from early discovery through clinical development.
  • Design, lead, and interpret pharmacokinetic, metabolism, disposition, bioanalytical, and PK/PD nonclinical studies.
  • Drive human PK projections, dose and regimen selection, and interpretation of emerging clinical data.
  • Select and lead CROs, laboratories, consultants, and other external partners, assuring study quality, data integrity, and timelines.
  • Review study protocols, reports, and datasets; identify pharmacokinetic and drug-metabolism risks early; and chart development strategies.
  • Author and review pharmacokinetics, bioanalytical, and related sections of regulatory documents, including INDs, CTAs, investigator brochures, and briefing documents.
  • Represent Pharmacokinetics on cross-functional project teams and governance forums, translating complex science into actionable recommendations for leadership.
  • Oversee deployment, standardization, and routine execution of Phoenix WinNonlin and related modeling platforms for data analysis.
  • Partner with the Innovation Lab and Business Development team to evaluate new assets and identify risks and opportunities.
  • Scout and introduce new methods, AI technologies, and external capabilities that improve pharmacokinetic prediction, accelerate development, and inform program decisions.
  • Cultivate scientific relationships within and outside the company.

Desired Qualifications

  • Experience using Phoenix WinNonlin for modeling and simulation, including PK/PD or other quantitative approaches.
  • Experience supporting regulatory interactions or submissions.
  • Experience building scientific capabilities, mentoring the next generation of talent, or leading internal/external partnerships.

About the Company

Tarsus Pharmaceuticals

Develops FDA-approved ophthalmic therapies

Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY (lotilaner ophthalmic solution 0.25%), an FDA-approved eye drop for Demodex Blepharitis. The product is applied as a medicated eye drop to kill Demodex mites and relieve eyelid inflammation. The company differentiates itself with a focused ocular/infectious-disease portfolio, an FDA-approved therapy, and active partnerships to expand its research and reach. Its goal is to address unmet medical needs, grow its product lineup through commercialization, and pursue new indications in eye care and infectious diseases.

Company size
201-500
Company stage
IPO
Headquarters
Irvine, CA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Tarsus Pharmaceuticals

See more jobs